OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

ABBVIE INC. DL-,01/  US00287Y1091  /

Frankfurt
2024-07-26  4:28:32 PM Chg. +4.5200 Volume Bid9:59:36 PM Ask9:59:36 PM Market Capitalization Dividend Y. P/E Ratio
171.7400EUR +2.70% 80
Turnover: 13,624.8000		 -Bid Size: - -Ask Size: - 301.14 bill.EUR - -
GlobeNewswire 07-01 Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
GlobeNewswire 07-01 OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in A...
GlobeNewswire 06-28 NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
GlobeNewswire 06-28 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire 06-28 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire 06-27 Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Ach...
GlobeNewswire 06-26 COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors
GlobeNewswire 06-25 CEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel’s $45 Per Share Deal is Being Investigated by BFA Law, Sh...
GlobeNewswire 06-24 OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell...
GlobeNewswire 06-22 CEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel’s $45 Per Share Offer is Being Investigated by BFA Law...
GlobeNewswire 06-21 Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest C...
GlobeNewswire 06-20 CEREVEL INVESTOR REMINDER: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law...
GlobeNewswire 06-20 OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of I...
GlobeNewswire 06-19 OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the B...
GlobeNewswire 06-19 Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire 06-18 CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...
GlobeNewswire 06-18 CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoi...
GlobeNewswire 06-17 CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
GlobeNewswire 06-17 Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, B...
GlobeNewswire 06-15 CEREVEL STOCK NOTICE: Think $45 Per Share is Too Low for Cerevel (Nasdaq: CERE)? Contact BFA Law abo...
Newsfile Corp 06-13 BioMed X Launches New US Institute in New Haven, CT
GlobeNewswire 06-13 Anima Biotech to Present at the Society for Medicines Research’s Modulating RNA with Oligonucleotide...
GlobeNewswire 06-13 LifeSci Advisors Announces Appointment of Chris Howerton Ph.D.
GlobeNewswire 06-13 CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investi...
GlobeNewswire 06-13 What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...